WallStSmart

AnaptysBio Inc (ANAB)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 158% more annual revenue ($606.42M vs $234.60M). INSM leads profitability with a -2.1% profit margin vs -5.6%. INSM earns a higher WallStSmart Score of 39/100 (F).

ANAB

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 5.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.32

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANAB3 strengths · Avg: 10.0/10
Operating MarginProfitability
61.8%10/10

Strong operational efficiency at 61.8%

Revenue GrowthGrowth
151.1%10/10

Revenue surging 151.1% year-over-year

Debt/EquityHealth
-11.7810/10

Conservative balance sheet, low leverage

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ANAB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.88B3/10

Smaller company, higher risk/reward

Price/BookValuation
49.2x2/10

Trading at 49.2x book value

Return on EquityProfitability
-24.5%2/10

ROE of -24.5% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ANAB

The strongest argument for ANAB centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 151.1% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ANAB

The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ANAB profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

ANAB is growing revenue faster at 151.1% — sustainability is the question.

ANAB generates stronger free cash flow (98M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AnaptysBio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?